The company further stated that the record date for payment of the interim dividend, if declared, has been fixed as Tuesday, September 30, 2025.
First quarter results
Glenmark Pharmaceuticals reported an 86.2% year-on-year (YoY) decline in net profit at ₹46.8 crore for the first quarter that ended June 30, 2025, down from ₹340.2 crore in Q1FY25. However, revenue increased slightly, up 0.6% at ₹3,264 crore against ₹3,244 crore in the same quarter last year.
Also Read: Glenmark Pharma announces India launch of blood cancer treatment Brukinsa
At the operating level, EBITDA dipped 1.4% to ₹580 crore in this quarter compared to ₹588.2 crore YoY.
The EBITDA margin was lower at 17.7% versus 18.1% in the April-July quarter of the previous fiscal.
In India, sales from Glenmark Pharmaceuticals’ formulation business in the first quarter of FY26 stood at ₹1,239.9 crore, compared with ₹1,196.2 crore a year ago, reflecting a 3.7% YoY growth.
In North America, the business registered revenue of ₹778 crore for this quarter, compared with ₹714.6 crore in the fourth quarter of FY25, marking an 8.9% quarter-on-quarter (QoQ) increase. The growth was driven by share gains in injectable product launches and partnered products.
Also Read: Glenmark Pharma's innovation arm signs exclusive licensing agreement with AbbVie for ISB 2001
Revenue from emerging markets, including RCIS, LATAM, MEA, and APAC, was ₹572.1 crore in the first quarter of FY26, compared with ₹570.8 crore in the year-ago period, registering a 0.2% YoY rise. The company continues to anticipate double-digit growth on a constant currency basis.
Shares of Glenmark Pharmaceuticals Ltd ended at ₹2,014.35, down by ₹70.25 or 3.37%, on the BSE today, September 22.